Evidence map›Paper›PMID 39886787›Full record

ReviewCurrent drug safety2026

Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature.

Yasmine Salem Mahjoubi, Fatma Zgolli, Israa Dahmani, Widd Kaabi, Sarrah Kastalli, Imen Aouinti, Sihem El Aidli

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Current drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasmine Salem MahjoubiDepartment of Collection and Analysis of Adverse Reactions, Faculty of Medicine of Tunis, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.ORCID 0000-0001-8597-3706
Fatma ZgolliDepartment of Collection and Analysis of Adverse Effects, Faculty of Medicine, Research unit: UR17ES12, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.
Israa DahmaniDepartment of Collection and Analysis of Adverse Effects, Faculty of Medicine, Research unit: UR17ES12, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.
Widd KaabiDepartment of Collection and Analysis of Adverse Effects, Faculty of Medicine, Research unit: UR17ES12, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.
Sarrah KastalliDepartment of Collection and Analysis of Adverse Effects, Faculty of Medicine, Research unit: UR17ES12, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.
Imen AouintiDepartment of Collection and Analysis of Adverse Effects, Faculty of Medicine, Research unit: UR17ES12, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.
Sihem El AidliDepartment of Collection and Analysis of Adverse Effects, Faculty of Medicine, Research unit: UR17ES12, National Center Chalbi Belkahia of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association. CASE PRESENTATION: A 53-year-old male patient with no prior medical history presented with septic arthritis and was initiated on TMP-SMX therapy. Within days, he developed muscle pain and weakness with laboratory tests revealing markedly elevated Creatine Kinase (CK) levels, consistent with rhabdomyolysis. Following the discontinuation of TMP-SMX, the patient's CK levels gradually decreased, and his symptoms resolved without further intervention.

conclusionTo our knowledge, this is the sixth reported case of TMP-SMX-associated rhabdomyolysis in an immunocompetent patient. This case highlights the need for clinicians to consider the potential for rhabdomyolysis in patients receiving TMP-SMX, regardless of their immune status, and to recognize that prompt withdrawal of the drug is critical for patient recovery.

Indexed as

Anti-Bacterial AgentsRhabdomyolysisTrimethoprim, Sulfamethoxazole Drug CombinationArthritis, InfectiousCreatine KinaseHumansMaleMiddle AgedAnti-Bacterial AgentsCreatine KinaseTrimethoprim, Sulfamethoxazole Drug CombinationAdverse drug reactionanti-bacterial agentsmyalgiarenal failurerhabdomyolysissulfamethoxazoletrimethoprim combination

Identifiers

PMID39886787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.